


In the Claims:

1. (Original) A compound of formula (I):



wherein

A and B represent the groups  $-(CH_2)_m-$  and  $-(CH_2)_n-$  respectively;

$R^1$  represents  $C_{1-6}$ alkyl;

$R^2$  represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy $C_{1-6}$ alkyl, trifluoromethyl, trifluoromethoxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $-(CH_2)_pC_{3-6}$ cycloalkyl,  $-(CH_2)_pOC_{3-6}$ cycloalkyl,  $-COC_{1-6}$ alkyl,  $-SO_2C_{1-6}$ alkyl,  $-SOC_{1-6}$ alkyl,  $-SC_{1-6}$ alkyl,  $-CO_2C_{1-6}$ alkyl,  $-CO_2NR^4R^5$ ,  $-SO_2NR^4R^5$ ,  $-(CH_2)_pNR^4R^5$ ,  $-(CH_2)_pNR^4COR^5$ , an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclyl group;

$R^3$  represents hydrogen or  $C_{1-6}$ alkyl;

$Ar^1$  represents an optionally substituted heteroaryl group;

$Ar^2$  represents an optionally substituted phenyl or an optionally substituted heteroaryl group;

Y represents a bond,  $-O-$ ,  $-C_{1-6}$ alkyl-,  $-CR^6R^7X-$ ,  $-XCR^6R^7-$ ,  $-NR^8CO-$  or  $-CONR^8-$ ;

X represents oxygen, sulfur,  $-SO-$  or  $-SO_2-$ ;

$R^4$  and  $R^5$  each independently represent hydrogen or  $C_{1-6}$ alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;

$R^6$  and  $R^7$  each independently represent hydrogen,  $C_{1-6}$ alkyl or fluoro;

$R^8$  represents hydrogen or  $C_{1-6}$ alkyl;

m and n independently represent an integer selected from 1 and 2;

p independently represents an integer selected from 0, 1, 2 and 3;

or a pharmaceutically acceptable salt, solvate or pharmaceutically acceptable derivative thereof.

2. (Original) A compound of formula (I) which is
- 5-(4-Chlorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(3-Methoxyphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(4-Methoxyphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(3,4-Difluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(2,4-Difluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(3-Chlorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(3-Fluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(4-Trifluoromethylphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(3-Trifluoromethylphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(4-Fluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(4-Fluorophenyl)-thiophene-2-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(4-Chlorophenyl)-thiophene-2-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
- 5-(4-Chloro-2-methylphenyl)-thiophene-2-sulfonic acid (2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;
- 5-Isloxazol-3-yl-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;
- 5-(2-Methylthiazol-5-yl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;

[2,3']Bithiophenyl-5-sulfonic acid (2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide;

[2,3']Bithiophenyl-5-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide;

5-(4-Chlorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amide;

5-(4-Fluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amide;

5-(2,4-Difluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amide; and

5-(3,4-Difluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amide.

3. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 ~~or claim 2~~ or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier therefor.

Claims 4-8. (Cancelled)

9. (Currently Amended) A method of treating a condition which requires modulation of dopamine receptors which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) according to claim 1 ~~or claim 2~~.

10. (Original) A method of treating a condition according to claim 9 wherein the condition is schizophrenia or substance abuse.